Form 4: STAAR Surgical COO Warren Foust Awarded Restricted Stock Units

Warren Foust, President and COO of STAAR Surgical, was granted restricted stock units (RSUs) on March 14, 2025, as part of an annual equity award and in connection with his promotion.

Summary

• Warren Foust, the President and COO of STAAR Surgical, received restricted stock units (RSUs) on March 14, 2025.
• 58,651 RSUs were granted as part of his annual equity award, vesting in three equal installments on March 14, 2026, March 14, 2027, and March 14, 2028 (approximately 19,550 shares per vesting date).
• An additional 29,326 RSUs were granted in connection with his promotion to President and COO, also vesting in three equal installments on the same dates (approximately 9,775 shares per vesting date).
• Each RSU represents the right to receive one share of STAAR Surgical's common stock upon vesting.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The promotion also adds a slightly positive sentiment.

Positives

• The grant of RSUs to the President and COO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment and performance from the executive.

Future Outlook

The vesting schedule of the RSUs suggests an expectation of continued service and contribution from the executive over the next three years.

Industry Context

Equity compensation is a common practice in the medical device industry to incentivize executives and align their interests with shareholders. RSU grants are a typical component of executive compensation packages.

Comparison to Industry Standards

• Comparing STAAR Surgical's executive compensation practices with those of similar-sized medical device companies like Glaukos or InMode would provide a benchmark for assessing the competitiveness and appropriateness of the RSU grants.
• Reviewing the vesting schedules and grant sizes relative to industry peers can offer insights into whether STAAR Surgical's compensation strategy is aligned with market norms.

Stakeholder Impact

• Shareholders may view the RSU grants positively as they incentivize management to improve company performance.
• Employees may see the promotion and equity grants as a sign of company growth and opportunity.

Key Dates